A former prostate cancer patient who got the all-clear said taking part in a trial that cut his radiotherapy treatments proved "life changing". While most patients have 20 days of radiotherapy over ...

Alpha Tau Medical Ltd (DRTS) announced an update on their ongoing clinical study. Study Overview – Alpha Tau Medical Ltd. (NASDAQ: DRTS) is launching a new safety study titled “A Safety Study of ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive global trial has found that a combination of two medications, enzalutamide ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...

From AI-generated biopsy reports to new imaging techniques, these are the latest developments in advanced prostate cancer research that your doctor may be keeping tabs on. Much of managing advanced ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care necessary in the follow-up journey, Mayo Clinic’s Department of Radiation ...

Researchers are targeting dormant tumour cells that might explain why some cancers reappear long after successful treatment.

Cardiovascular (CV) disease is a leading cause of death among patients with prostate cancer. | Cardiovascular (CV) disease is ...

SUCCEED trial enables remote participation for small cell lung cancer patients, addressing location barriers and enhancing research opportunities. NXP800 shows promise in recurrent, platinum-resistant ...

For years, prostate cancer specialists hit a wall when prostate-specific antigen (PSA) levels crept up after definitive treatment. The cancer was likely back — but where? And to what extent? Bone plus ...